Profusa's Freefall: 58% Intraday Drop as Technicals Signal Desperation

Summary
• Profusa (PFSA) plunges 57.8% to $0.4182, erasing $0.1269 from its opening price
• Turnover surges 501% to $123.6M, signaling panic-driven liquidation
• RSI collapses to 16.52, the lowest level in months

Profusa’s stock is in freefall, trading at its intraday low of $0.4087 after a brutal 57.8% drop from its 13:46 ET price. The medical devices sector remains muted, with Medtronic (MDT) up 0.56%. This collapse defies sector trends and lacks immediate news catalysts, pointing to technical breakdowns and speculative unwinding.

Technical Collapse as Short-Term Bearish Momentum Accelerates
The selloff is driven by a confluence of bearish technical signals. RSI at 16.52 confirms oversold conditions, while the MACD (-0.15) and negative histogram (-0.17) highlight deteriorating momentum. Price has cratered below the 30D MA (0.47) and Bollinger Bands’ lower bound (0.2376), triggering stop-loss cascades. The 501% surge in turnover suggests forced liquidation, likely from leveraged positions or short-term traders.

Medical Devices Sector Slight Gains as Profusa's Plunge Defies Sector Strength
While the medical devices sector remains neutral, Medtronic (MDT) is up 0.56%, contrasting PFSA’s collapse. The sector’s modest gains suggest no direct link to PFSA’s move. However, PFSA’s extreme volatility—trading 57.8% below its open—indicates isolated speculative pressure rather than sector-wide weakness.

Technical Deterioration: ETFs and Cash-Flow Strategies for PFSA's Volatility
• RSI: 16.52 (oversold)
• MACD: -0.15 (bearish), Signal Line: -0.168 (bearish), Histogram: 0.017 (diverging)
• Bollinger Bands: 0.6183 (upper), 0.4279 (middle), 0.2376 (lower)
• 30D MA: 0.4702 (below price)

PFSA’s technicals paint a dire picture. The stock is trapped near its 52W low (0.265) and far below the 30D MA. Traders should avoid longs and consider cash-secured puts for downside protection. The 0.4015–0.4106 support zone is critical; a break below triggers a test of the 0.2376 Bollinger floor. No options are available for analysis, but leveraged ETFs remain absent, limiting synthetic exposure. Aggressive short-sellers may target 0.30 as a potential target, but liquidity risks persist.

Backtest Profusa Stock Performance
Hi there—here is what I’ve done so far and what I’ve found:1. Retrieved full-history daily OHLC data for PFSA.O from 1 Jan 2022 to 11 Sep 2025. 2. Tried two different ways to define the “58 % intraday surge” event: • Daily close ≥ 58 % above the previous close (our first attempt), • Daily high ≥ 58 % above the day’s low (second attempt). 3. In both cases the event-selection step returned an empty list, so the back-test engine could not run (division-by-zero error).In short, during the 2022-to-present window PFSA has not had a day that meets either of those 58 % thresholds under the two most common definitions, so there is nothing to back-test.How would you like to proceed?A. Lower the threshold (e.g., 40 %, 30 %) to make sure we capture enough events. B. Keep the 58 % threshold but extend the look-back period further into the past. C. Use a different definition of “intraday surge” (for example, high vs. previous close instead of high vs. low). D. Something else?Let me know your preference and I’ll rerun the analysis accordingly.

Immediate Action Required: PFSA's Technicals Suggest Further Decline
PFSA’s technical collapse shows no signs of abating. The RSI at 16.52 and MACD divergence signal continued weakness, while the 0.4015 support level is under threat. Medtronic’s 0.56% gain underscores the sector’s resilience, contrasting PFSA’s isolation. Investors should prioritize liquidity and avoid speculative longs. Watch for a breakdown below 0.4015 or a catalyst-driven rebound above 0.47. For now, cash-secured puts or a wait-and-see approach is prudent.